Foscarbidopa/foslevodopa: Difference between revisions
Jump to navigation
Jump to search
Content deleted Content added
←Created page with ''''Foscarbidopa/foslevodopa''' (development name '''ABBV-951''') is a combination of prodrugs for levodopa and carbidopa that is developed by AbbVie to treat Parkinson's disease.<ref>{{cite journal |last1=Rosebraugh |first1=Matthew |last2=Kym |first2=Philip |last3=Liu |first3=Wei |last4=Facheris |first4=Maurizio |last5=Benesh |first5=Janet |title=A Novel Levodopa/Carbidopa Prodrug (ABBV-951) 24-Hour Continuous Subcutaneous Infusion Treat...' |
(No difference)
|
Revision as of 02:44, 25 November 2023
Foscarbidopa/foslevodopa (development name ABBV-951) is a combination of prodrugs for levodopa and carbidopa that is developed by AbbVie to treat Parkinson's disease.[1][2][3][4][5] The combination was refused FDA approval in early 2023.[6]
References
- ^ Rosebraugh, Matthew; Kym, Philip; Liu, Wei; Facheris, Maurizio; Benesh, Janet (9 April 2019). "A Novel Levodopa/Carbidopa Prodrug (ABBV-951) 24-Hour Continuous Subcutaneous Infusion Treatment for Parkinson's Disease (P3.8-037)". Neurology. 92 (15 Supplement). ISSN 0028-3878.
- ^ Facheris, Maurizio; Criswell, Susan; Pavasia, Nirav; Pahwa, Rajesh; Locke, Charles; Robieson, Weining; Shprecher, David (14 April 2020). "Safety and Tolerability During a 4-Week Continuous Subcutaneous Infusion of ABBV-951, a New Drug Formulation for the Treatment of Parkinson's Disease: Final Results of a Phase 1b Study (1384)". Neurology. 94 (15 Supplement). ISSN 0028-3878.
- ^ Facheris, Maurizio; Benesh, Janet; Streit, Janet; Robieson, Weining; Zadikoff, Cindy; Standaert, David (14 April 2020). "Safety and Tolerability in Parkinson's Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study (4233)". Neurology. 94 (15 Supplement). ISSN 0028-3878.
- ^ Rosebraugh, Matthew; Kym, Philip; Liu, Wei; Facheris, Maurizio (14 April 2020). "ABBV-951 Maintains Stable Levodopa Exposure following Subcutaneous Infusion in Parkinson's Disease Patients (543)". Neurology. 94 (15 Supplement). ISSN 0028-3878.
- ^ Facheris, Maurizio; Robieson, Weining; Fisseha, Nahome; Standaert, David (13 April 2021). "Efficacy and Safety of Foslevodopa/Foscarbidopa Versus Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients: Design of a Phase 3, Randomized, Double-Blind, Double-Dummy, Active Controlled 12-Week Trial (2251)". Neurology. 96 (15 Supplement). ISSN 0028-3878.
- ^ https://www.fiercepharma.com/pharma/abbvies-parkinsons-combo-drug-hits-wall-fda-questions-delivery-pump. Retrieved 25 November 2023.
{{cite news}}: Missing or empty|title=(help)